What's Happening?
bioAffinity Technologies, a biotechnology company, has announced a significant increase in the sales of its CyPath® Lung diagnostic test, which is designed for early detection of lung cancer. The company reported a more than 200% year-over-year growth
in sales for the second quarter of 2026, with a 30% increase over the previous quarter. This growth is attributed to increased utilization among existing clients and a 155% rise in physician offices ordering the test compared to the same period in 2025. CyPath® Lung uses advanced flow cytometry and artificial intelligence to identify cancer-related cells in patient sputum, offering a noninvasive alternative for detecting lung cancer. The test has demonstrated high sensitivity and specificity in clinical trials, providing physicians with a reliable tool to make informed decisions about patient care.
Why It's Important?
The surge in CyPath® Lung sales highlights a growing trend towards noninvasive diagnostic tools in the medical field, particularly for diseases like lung cancer where early detection is crucial. This development is significant for the healthcare industry as it reflects a shift towards more patient-friendly diagnostic methods that can reduce the need for invasive procedures. The increased adoption of CyPath® Lung by physicians suggests a broader acceptance of AI-driven diagnostics, which could lead to improved patient outcomes and reduced healthcare costs. As the number of patients with indeterminate pulmonary nodules is expected to rise, tools like CyPath® Lung could play a critical role in managing patient care and reducing unnecessary medical interventions.
What's Next?
bioAffinity Technologies plans to continue expanding its market presence by increasing the utilization of CyPath® Lung among existing clients and entering new markets. The company is also advancing its research and development efforts to include diagnostic tests for other lung diseases such as asthma and COPD. A large-scale longitudinal clinical study is underway to further validate CyPath® Lung, and the company aims to use the test to monitor lung cancer survivors post-treatment. These initiatives are expected to enhance the clinical impact of bioAffinity's technology platform and support the development of personalized treatment strategies for lung disease patients.
